CURRICULUM VITAE

William H. Bradley MD

Professor

Department of Obstetrics and Gynecology

Division of Gynecologic Oncology

OFFICE ADDRESS:

Froedtert/MCW Laboratory Building

9200 W Wisconsin Ave

Milwaukee, WI 53226

Phone: 414-805-6606

Fax:  414-805-6622

E-mail: [email protected]

PLACE OF BIRTH:   Fort Monmouth, NJ

CITIZENSHIP:  USA

EDUCATION:

       Undergraduate

9/1988 - 5/1989 University of Saint Andrews, Saint Andrews, Scotland

9/1989 - 6/1992 BA - Philosophy, Macalester College, St. Paul, MN

Post baccalaureate

9/1992 - 6/1993 Department of Philosophy, New School for Social Research, New York, NY

3/1994 - 12/1995 Pre-medical course work, University of Minnesota, Minneapolis, MN

Medical Education

9/1996 - 5/2000 MD, University of Minnesota, Minneapolis, MN

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

6/2000 - 6/2004 Residency, University of Minnesota, Department of Obstetrics, Gynecology and Women’s Health, Minneapolis, MN

7/2005 - 6/2008 Fellow, Division of Gynecologic Oncology, Mount Sinai Medical Center

FACULTY APPOINTMENTS:

7/2008 – 12/2014 Assistant Professor, Division of Gynecologic Oncology, Medical College of Wisconsin, Milwaukee, WI

12/2014-Present Associate Professor, Division of Gynecologic Oncology, Medical College of Wisconsin, Milwaukee, WI

Administrative Appointments:   

6/2020-current: Director of Clinical Research, Department of OB/GYN

7/2012-current: Academic Incentive Committee, Department of OB/GYN (Chair 6/2018-6/2020)

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

7/2008-Present Staff Physician, Froedtert Lutheran Memorial Hospital, Milwaukee, WI

2010-Present Staff Physician, Community Memorial Hospital, Menominee Falls, WI

2010-Present Staff Physician, Saint Joseph’s Hospital, West Bend, WI

BOARDS AND CERTIFICATION:

    Gynecologic Oncology

ADMINISTRATIVE APPOINTMENTS

                2010-present: Institutional Principal Investigator, Gynecologic Oncology Group

                Current Co-PI for NRG Oncology

                2011-2013: Faculty Council, Medical College of Wisconsin

2013- present: Scientific Advisory Committee, Clinical Cancer Center, Froedtert Hospital, Current Vice-Chair

                2011-present: Clinical Cancer Center PNT Committee

                2012-2013: Member Ad Hoc Robotic Surgery Committee, Froedtert Hospital

                2013-2016: Member Program Committee, Milwaukee Gynecologic Society

                2013-present: Member Phase I and Developmental Therapeutics Committee, NRG

                2020-present: Member of advisory council for GOG Foundation

AWARDS AND HONORS:

2013-current Best Doctors in America

2013 CREOG National Faculty Award for Excellence in Resident Education

2007 Physician of the Year, Fellow Award, Mount Sinai

5/2004 Organon Award, Best Basic Science Paper, Resident Research Day

2003 - 2004 Chief Resident, Department of Obstetrics and Gynecology, University of Minnesota

2/2003 - 3/2003 Galloway Fellowship, Memorial Sloan-Kettering Cancer Center

2001 - 2002 Berlex Teaching Resident of the Year

1997-1998 Jean Mata Scholarship

1996-1997 Zwick Medical Scholarship

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

American College of Obstetrics and Gynecology  (Fellow)

Society of Gynecologic Oncologists  (Full Member)

American Board of Obstetrics and Gynecology  (Fellow)

American Society of Clinical Oncologists (Member)

American College of Surgeons (Member)

International Society of Gynecologic Cancer (Member)

Society of Gynecologic Oncology (Full Member)

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Peer Reviewed

Title:                     Clinical Research Scholars Program (8UL1TR000055)

Source:                  CTSI

Role:                     Clinical Research Scholar

Dates:                    7/2011-6/2013

Direct Funds:        n/a

Peer Reviewed

Title:                       The EndoBARR Trial (NCT03694262)

Source:                  Genentech/Clovis Oncology

Role:                       Principal Investigator

Dates:                    07/19/2019 –Current

Direct Funds:         $539,931 (total for all years)

Peer Reviewed

Title:                       A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or

Source:                  Hookipa Biotech GmbH

Role:                       Principal Investigator

Dates:                    11/16/2020-Current

Direct Funds:         $

Peer Reviewed

Title:                       UG1 CA233198 

Source:                  NCI

Role:                      Co-Investigator

PI:                           Stuart Wong, MD               

Dates:                    03/07/2019 – 02/28/2025

Direct Funds:        $799,283 (total for all years)

Women’s Health Research Program/Falk Medical Research Trust  2011-2014: $25,000

Corrigan Fund: 2003-2004: $5,000

Gynecologic Oncology Group, Institutional Principal Investigator. 

Clinical Research/ Clinical Trials:

NRG-GY021: A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer

NRG-GY001: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum

NRG-GY003: Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NRG-GY004:A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

(COCOS)

NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

NRG-CC002: Pre-Operative Assessment and Post-Operative Outcomes Of Elderly Women With Gynecologic Cancers

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]

NRG GY009:Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

 NRG-GY017: Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

NRG-GY020: A Phase III Randomized Trial of Radiation +/- MK-3475

(Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

GOG-086P: A Three Arm Randomized Phase II Study Of Paclitaxel/carboplatin/bevacizumab (NSC#704865, IND#7921), Paclitaxel/carboplatin/temsirolimus (NSC#683864,  IND#61010) And Ixabepilone (NSC#710428, IND# 59699)/Carboplatin/Bevacizumab As Initial Therapy For Measurable Stage III Or IVA, Stage IVB, Or Recurrent  Endometrial Cancer

GOG-136: Acquisition Of Human Gynecologic Specimens To Be Used In Studying The Causes, Diagnosis, Prevention, And Treatment Of Cancer

GOG-186H: A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysis NSC # 729968, BB-IND #13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

GOG-207: A Randomized Double-blind Phase II Trial Of Celecoxib, A Cox-2 Inhibitor, In The Treatment Of Patients With Cervical Intraepithelial Neoplasia 2/3 Or 3 (CIN 2/3 Or 3)

(IND #69,656)

GOG-209: Randomized Phase III Trial Of Doxorubicin/Cisplatin/Paclitaxel And Carboplatin/Paclitaxel In Patients With Stage III & IV Or Recurrent Endometrial Cancer

GOG-214: Phase II Double Blind Randomized Trial Evaluating The Biologic Effect Of Levonorgestrel On The Ovarian Epithelium In Women At High Risk For Ovarian Cancer

GOG-218: A Phase III Trial Of Carboplatin And Paclitaxel Plus Placebo Versus Carboplatin And Paclitaxel Plus Concurrent Bevacizumab Followed By Placebo, Versus Carboplatin And Paclitaxel Plus Concurrent And Extended Bevacizumab, In Women With Newly Diagnosed, Previously Untreated, Stage III Or IV, Epithelial Ovarian, Primary Peritoneal Or Fallopian Tube Cancer

GOG-212: A Randomized Phase III Trial Of Maintenance Chemotherapy Comparing 12, Monthly Cycles Of Single Agent Paclitaxel Or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse In Women With Advanced Ovarian, Primary Peritoneal Or Fallopian Tube Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane

GOG-213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865,IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer

GOG-225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Peritoneal Cancer Progression-Free Survival?

GOG-227E: A Phase II Evaluation Of Cetuximab (Erbitux®, C225, NSC# 714692) In The Treatment Of Persistent Or Recurrent Squamous Or Non-squamous Cell Carcinoma Of The Cervix

GOG-229O: A Randomized Phase II Study With A Phase I Lead-In To Assess The Antitumor Efficacy Of The MEK Inhibitor Trametinib Alone Or In Combination With GSK2141795, An AKT Inhibitor In Patients With Recurrent Or Persistent Endometrial Cancer

GOG-235: A Prospective, Longitudinal Study Of YKL-40 In Patients With Figo Stage III Or IV Invasive Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Undergoing  Primary Chemotherapy

GOG-240: A Randomized Phase III Trial Of Cisplatin Plus Paclitaxel With And Without NCI-supplied Bevacizumab (NSC #704865, IND #113912) Versus The Non-Platinum Doublet, Topotecan Plus Paclitaxel, With And Without NCI-supplied Bevacizumab, In Stage IVB, Recurrent Or Persistent Carcinoma Of The Cervix

GOG-241: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab (NSC #704865, IND #113912) Compared With Oxaliplatin and Capecitabine+/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

GOG-244:The Lymphedema And Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, And Impact In Newly Diagnosed Patients

GOG-249: A Phase III Trial Of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy In Patients With High Risk, Early Stage Endometrial Carcinoma

GOG-252: A Phase III Clinical Trial Of Bevacizumab With IV Versus IP Chemotherapy In Ovarian, Fallopian Tube And Primary Peritoneal Carcinoma NCI-supplied Agent(s): Bevacizumab (NSC #704865, IND #113912)

GOG-255: A Phase II Randomized, Double-Blind Trial Of A Polyvalent Vaccine-KLH Conjugate (NSC 748933 IND# 14384) + Opt-821 Versus Opt-821 In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Cancer Who Are In Second Or Third Complete Remission

GOG-258: A Randomized Phase III Trial Of Cisplatin And Tumor Volume Directed Irradiation Followed By Carboplatin And Paclitaxel Vs. Carboplatin And Paclitaxel For Optimally Debulked, Advanced Endometrial Carcinoma

GOG-261: A Randomized Phase III Trial Of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel In Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent Or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) Of The Uterus Or Ovary

GOG-262: A Randomized Phase III Trial Of Every-3-weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent And Consolidation Bevacizumab (NSC #704865, IND#113912) In The Treatment Of Primary Stage II, III Or IV Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer

GOG-263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

GOG-267: Quality Of Life And Care Needs In Patients With Persistent Or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, And Peritoneal Cancer

GOG-265: A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND #13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

GOG-268: A Phase II Evaluation Of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864, IND# 61010) In Combination With Carboplatin And Paclitaxel Followed By Temsirolimus (CCI-779) Consolidation As First-Line Therapy In The Treatment Of Stage III-IV Clear Cell Carcinoma Of The Ovary

GOG-272: Pilot Study Of Standard Therapy For Prevention Of Nausea And Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy

GOG-273: Chemotherapy Toxicity In Elderly Women With Ovarian, Primary Peritoneal Or Fallopian Tube Cancer

GOG-274: A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treament for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial

GOG-281: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib

(GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

GOG-286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

GOG-277: A Phase III Randomized Trial of Gemcitabine (NSC # 613327) Plus Docetaxel (NSC # 628503) Followed by Doxorubicin (NSC # 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

GOG 9927: Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888) In Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer

GOG 9928: A Phase I Study of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (IND # 12,484) Administered in Combination with Pegylated Liposomal Doxorubicin (PLD, Doxil® (NSC# 712227 or Lipodox) (NSC#673089) In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

GOG-3001: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

GOG-3003: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

GOG-3004: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy

GOG 3013: A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab* (MSB0010718C) Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone in Patients with Platinum-Resistant/Refractory Ovarian Cancer

GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer

GOG 3041: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

(DUO-E)

GOG 3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel with or without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

GOG 3012: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab and Rucaparib Combination Maintenance following Front-Line Platinum-based Chemotherapy in Ovarian Cancer Patients

GOG 3023: Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®-TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer

GOG 3009: Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: Aim2cerv

GOG 3011: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) versus Investigator's Choice of Chemotherapy in Women with Folate Receptor Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Ergomed-ZN-C3-004: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

CELSION-201-17-201: Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

LEAP DEK-DKKI-P204: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer

CORCEPT: A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

IMMUNOGEN: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

ADVAXIS: Phase 1-2 Study of MEDI4736 Alone or in Combination with ADXS11-001 in Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer

Amgen TRINOVA 1: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

AZ SOLO3: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations

Programmatic Developments:

Educational Programs:

2/2019- present, ACGME approved Gynecologic Oncology Fellowship

Community Service Activities:

2008-present Medical Advisory Board Member, Wisconsin Ovarian Cancer Alliance

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Local/Regional

Expression and Activity of Cathepsin B in Benign and Malignant Endometrial Tissue, Resident Research Day, University of Minnesota, 5/2004

Recurrent Leiomyosarcoma, Multidisciplinary Grand Rounds, Mount Sinai Medical Center, 10/21/2005

Glassy Cell Carcinoma of the Uterine Cervix, Multidisciplinary Grand Rounds, Mount Sinai Medical Center, 12/16/2005

Intraperitoneal Chemotherapy for Ovarian Cancer:  GOG 172, before and beyond, Division of Gynecologic Oncology, Mount Sinai Medical Center, 1/24/2006

Management of the Adnexal Mass, Department of Surgery, Mount Sinai Medical Center, 2/15/2006

A Case of Vaginal Delivery Complicated by Hemorrhage, Joint Department of Obstetrics and Gynecology and Department of Anesthesia Grand Rounds, Mount Sinai Medical Center, 10/25/2006

Management of Early Ovarian Carcinoma, Division of Gynecologic Oncology, 1/16/2007

Chemoradiation and Cervical Cancer, Mount Sinai Medical Center, Division of Radiation Oncology, 4/24/2007

Ovarian Cancer and Subacute Cerebellar Degeneration, Multidisciplinary Grand Rounds, Mount Sinai Medical Center, 4/27/2007

Ovarian Cancers in the Pediatric Population, Multidisciplinary Grand Rounds, Mount Sinai Medical Center, 6/22/2007

Perimenopausal Bleeding, 11th Annual Women’s Health Conference, Department of Obstetrics and Gynecology, Medical College of Wisconsin, 4/24/2009

Ovarian Cancer, Future Directions, Wisconsin Ovarian Cancer Alliance, 5/2/2010

Gynecologic Cancer Screening, 14^th Annual Women’s Health Conference, Department of Obstetrics and Gynecology, Medical College of Wisconsin, 4/27/2012

Biomarkers in Ovarian Cancer, President’s Advisory Counsel, Froedtert Hospital, 9/11/2012

Management of Ovarian Cancer, Wisconsin Ovarian Cancer Alliance, 4/28/2013

Practical Components for Early Phase Discovery.  November 5, 2019, Ovarian Cancer, Midwest Focus

Patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOTOV26/GOG-3012 trial. Sept 10, 2020 Heartland Association of Gynecologic Oncology

Evaluation of an individualized starting dose of niraparib in the PRIMA/ENGOTOV26/GOG-3012 study. Sept 10, 2020 Heartland Association of Gynecologic Oncology

Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by BRCA and homologous recombination status: PRIMA/ENGOT-OV26/GOG3012 study.  Sept 10, 2020 Heartland Association of Gynecologic Oncology

National

Expression of C-kit Antigen in Low and High Grade Endometrial Stromal Sarcomas; Outcomes and Recurrence Patterns as Related to C-Kit, Mid-Atlantic Gynecologic Oncology Society, Durham, NC, 10/9/2003 - 10/11/2003

Implications of Hysteroscopy on Peritoneal Cytology in Endometrial Cancer, Presentation, Mid-Atlantic Gynecologic Oncology Society, Durham, NC, 10/9/2003 - 10/11/2003

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1.  SGO Virtual Annual meeting, March 20, 2021 

An open label, non-randomized multisite phase II trial combining Bevacizumab, Atezolizumab, and Rucaparib for the treatment of previously treated recurrent and progressive endometrial carcinoma. American Society of Clinical Oncology, Chicago, Il. June 7, 2022

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Melissa A. Geller, M.D., Peter A. Argenta, M.D., William H. Bradley, M.D., Katherine Dusenbery, M.D.,  Doris Brooker, M.D.,  Levi S. Downs, M.D., Patricia L. Judson, M.D., Linda F. Carson, M.D., Matthew P. Boente, M.D.  Treatment and Recurrence Patterns in Endometrial Stromal Sarcomas and the Relation to C-Kit Expression. Gynecologic Oncology. 95(3):632-636, Dec. 2004

2. William H. Bradley, M.D., Matthew P. Boente, M.D., Peter A. Argenta, M.D., Levi S. Downs, M.D., Patricia L. Judson, M.D., Linda F. Carson, M.D.  Hysteroscopy and Cytology in Endometrial Cancer.  Obstetrics and Gynecology.  104(5 Pt 1):1030-1033, Nov. 2004

3. Charles A. Leath, III, M.D., Warner K. Huh, M.D., Johnny Hyde, Jr. M.D., David E. Cohn, M.D., Kimberly E. Resnick, M.D., Nicholas P. Taylor, M.D., Matthew A. Powell, M.D., David G. Mutch, M.D., William H. Bradley, M.D., Melissa A. Geller, M.D., Peter A. Argenta, M.D., Michael A. Gold, M.D.  A Multi-institutional Review of Outcomes of Endometrial Stromal Sarcoma.  Gynecologic Oncology. June 2007;105(3):30-634

4. Jenny Tang M.D., David Bub M.D., William H. Bradley, M.D., Liane Deligdish M.D., Nemish Nagarsheth M.D.  Utero-Subfascial Fistula and Emerging Necrotizing Fasciitis resultant from Post-Cesarean Section Endometritis.  Gynecology and Obstetrics, Current Medical Literature.  Vol 12(3):73-76, 2007

5. Konstantin Zakashansky, M.D., William H. Bradley, M.D., Farr Nezhat, M.D.  New techniques in radical hysterectomy.  Current Opinion in Obstetrics and Gynecology. 2008 Feb;20(1):14-9.

6. William H. Bradley, M.D., Peter R. Dottino, M.D., Jamal Rahaman, M.D..  Paraneoplastic Cerebellar Degeneration in Ovarian Carcinoma: Case Report and Review of Immune Function. International Journal of Gynecologic Oncology.  2008 Nov-Dec;18(6):1364-7

7. William H. Bradley, M.D., Paul Lima, MS, Lisa Rogers, BS, Charles Blomquist, PhD, Levi S Downs, M.D.  Endometrial carcinoma expresses an increased cathepsin B/D ratio.  Gynecologic Oncology. 2008 Jan;108(1):84-9.

8. Herbert Gretz, M.D., William H. Bradley, M.D., Konstantin Zakashansky, M.D., Deborah Loeb Bohren, Kenneth Kreiger, Ph.D., Elizabeth Rubin, Alan Skolow, M.D..  Patient Clinic Factors on Utilization of Hysterectomy in New York, 2001-2005. American  Journal of  Obstetrics and Gynecology. 2008 Oct;199(4):349.e1-5

9. Herbert Gretz, M.D., William H. Bradley, M.D., Konstantin Zakashansky, M.D., Deborah Loeb Bohren, Kenneth Kreiger, PhD, Elizabeth Rubin, Alan Skolow, M.D..  Effect of Physician Gender and Specialty on Utilization of Hysterectomy in New York, 2001-2005. Am J Obstet Gynecol. 2008 Oct;199(4):347.e1-6

10. Konstantin Zakashansky, M.D., William H. Bradley, M.D., Linus Chuang, M.D., Jamal Rahaman, M.D., Peter Dottino, M.D.  Recent advances in the surgical management of cervical cancer. Mt Sinai Journal of Medicine.  2009 December;76(6): 567-76

11. Kevin H. Eng, Ph.D., Sijian Wang, Ph.D., William H. Bradley, M.D., Janet S. Rader, M.D., Christina Kendziorski, Ph.D.  Pathway-Index Models for Construction of Patient-Specific Risk Profiles.  Statistics in Medicine, Vol 32(9), 30 April, 2013, 1524-1535

12. Kharofa J, Morrow N, Kelly T, Rownd J, Paulson E, Rader J, Uyar D, Bradley W, Erickson B.  3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes. Brachytherapy. 2014 Jul-Aug;13(4):319-25. doi: 10.1016/j.brachy.2014.03.001.

13. Kevin H. Eng, Ph.D., Bret M. Hanlon, Ph.D., William H. Bradley, M.D., J. Brian Szender, M.D.  Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.  Gynecologic Oncology (2015), doi:10.1016/j.ygyno.2015.09.011

14. William H. Bradley, M.D., Kevin H. Eng, Ph.D., Min Le, Ph.D., A. Craig Mackinnon, M.D., Ph.D., Christina Kendziorski, Ph.D., Janet S. Rader, M.D.  Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma. BMC Clinical Pathology 2015, 15:17. doi: 10.1186/s12907-015-0017-1

15. Choi, J., Ye, S., Eng, K.H., Kornthauer, K. Bradley, W.H., Rader, J.S., Kendziorski, C., IPI59: an actionable biomarker to improve treatment response in serous ovarian carcinoma.  Statistics in Biosciences, doi10.1007/s12561-01609144-1. 

16. Shirley J. Hinshaw, M.D., Stephanie Gunderson, M.D., Daniel Eastwood, M.S., William H. Bradley, M.D. Endometrial Carcinoma: The Perioperative and Long-Term Outcomes of Robotic Surgery in the Morbidly Obese.  Journal of Surgical Oncology, 2016 Dec;114(7):884-887.  Doi: 10.1002/jso.24417 PMID: 27566529

17. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Gynecologic Oncology. 2017 Jan 12.  Doi:10.1016/j.ygyno.2016.11.033.  PMID: 28089376

18. The Cancer Genome Atlas Research Network.  Integrated genomic and molecular characterization of cervical cancer.  Nature.  http://dx.doi.org/10.1038/nature21386 (2017) PMID: 28112728

19. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. PMID: 28453702

20. Pediatric Gynecologic Cancers. Pommert L, Bradley W. Curr Oncol Rep. 2017 Jul;19(7):44. doi: 10.1007/s11912-017-0604-7. Review. PMID: 28501984

21. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C.Gynecol Oncol. 2017 Sep;146(3):477-483. doi: 10.1016/j.ygyno.2017.07.135. Epub 2017 Jul 27.PMID:28756871

22. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM.Gynecol Oncol. 2017 Nov;147(2):283-290 PMID: 28802766

23. IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients.Choi J, Ye S, Eng KH, Korthauer K, Bradley WH, Rader JS, Kendziorski C. Stat Biosci. 2017 Jun;9(1):1-12 PMID: 28966695

24. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L.Gynecol Oncol. 2018 May 17 PMID: 29778506

25. Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.  Harold JA, Free SC, Bradley WH.  Gynecol Oncol Rep. 2018 Oct 28;26:91-93. doi: 10.1016/j.gore.2018.10.011. eCollection 2018 Nov. PMID: 30426062

26. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.  Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.  N Engl J Med. 2018 Oct 21  PMID: 30345884

27. Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer.  Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH.  Int J Gynecol Cancer. 2019 Jan;29(1):53-59. doi: 10.1136/ijgc-2018-000008. PMID:30640684

28. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.  Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.  PMID:31076365

29. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.  González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.  N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962.

30. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.  Chen C, Gupta P, Parashar D, Nair GG, George J, Geethadevi A, Wang W, Tsaih SW, Bradley WH, Ramchandran R, Rader JS, Chaluvally-Raghavan P, Pradeep S.  Oncogene. 2020 Feb 6. doi: 10.1038/s41388-020-1194-7. [Epub ahead of print]  PMID: 32029900

31. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. J Clin Oncol. 2020 Oct 20;38(30):3528-3537. doi: 10.1200/JCO.20.00799. Epub 2020 Aug 4. PMID: 32749942

32. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13. PMID: 33862001

33. GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study.  Thaker PH, Bradley WH, Leath CA, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD.Clin Cancer Res. 2021 Jul 29:clincanres.0360.2021. doi: 10.1158/1078-0432.CCR-21-0360. Online ahead of print.PMID: 34326131 

34. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.

Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.Gynecol Oncol. 2021 Aug 2:S0090-8258(21)00578-3. doi: 10.1016/j.ygyno.2021.07.016. Online ahead of print.PMID: 34353615

35. GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.  Thaker PH, Bradley WH, Leath CA 3rd, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD. Clin Cancer Res. 2021 Oct 15;27(20):5536-5545. doi: 10.1158/1078-0432.CCR-21-0360. Epub 2021 Jul 29. PMID: 34326131 Clinical Trial.

36. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.  Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Gynecol Oncol. 2021 Oct;163(1):41-49. doi: 10.1016/j.ygyno.2021.07.016. Epub 2021 Aug 2. PMID: 34353615 Clinical Trial.

37. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.  Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P. Cancer Res. 2021 Oct 15;81(20):5336-5352. doi: 10.1158/0008-5472.CAN-21-0483. Epub 2021 Aug 11. PMID: 34380633

38. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.  Wenzel L, Huang HQ, Cella D, McKinney CO, Zevon MA, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, von Gruenigen VE. Gynecol Oncol. 2021 Nov;163(2):392-397. doi: 10.1016/j.ygyno.2021.08.028. Epub 2021 Sep 20. PMID: 34548162

39. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.  Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26. PMID: 34715071 Clinical Trial.

40. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Rader JS, Pradeep S, Chaluvally-Raghavan P. Cancers (Basel). 2022 Feb 15;14(4):958. doi: 10.3390/cancers14040958. PMID: 35205706

41. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A. Gynecol Oncol. 2022 May 9:S0090-8258(22)00253-0. doi: 10.1016/j.ygyno.2022.04.012. Online ahead of print. PMID: 35550709

42. Same-Day Discharge After Robotic Hysterectomy: A Resource Utilization and Quality Improvement Project. McAlarnen LA, Maurer JE, Knaub A, Hopp E, Streitenberger K, Bishop E, Bradley W, Rader J, Uyar D. WMJ. 2022 Oct;121(3):243-246. PMID: 36301654

43. A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor.  Summey RM, Rader JS, Moh M, Bradley W, Uyar D, Bishop E, McAlarnen L, Hopp E.  Gynecol Oncol Rep. 2022 Dec 13;44:101118. doi: 10.1016/j.gore.2022.101118. eCollection 2022 Dec. PMID: 36579182

44. Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.  Yin X, Davi R, Lamont EB, Thaker PH, Bradley WH, Leath CA 3rd, Moore KM, Anwer K, Musso L, Borys N.  JCO Clin Cancer Inform. 2023 Jan;7:e2200103. doi: 10.1200/CCI.22.00103.  PMID: 36608308

45. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators.  J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. Epub 2022 Sep 9.  PMID: 36082969

46. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. Gynecol Oncol. 2023 Mar 29;172:82-91. doi: 10.1016/j.ygyno.2023.03.013. Online ahead of print. PMID: 37001446

Books, Chapters, and Reviews

Bradley WH, Hopp EE. Salpingoophorectomy.  The SCORE PORTAL.  http://www.surgcialcore.org.  

Bradley WH, Hopp EE. Hysterectomy.  The SCORE PORTAL.  http://www.surgcialcore.org.  Published June 29, 2016

William H. Bradley M.D., Farr Nezhat M.D.  Hysteroscopy and Endometrial Cancer. Nezhat's Video-Assisted and Robotic-Assisted Laparoscopy and Hysteroscopy, 4^th Edition.  Cambridge University Press, New York, NY. 2008.  Pp 577-582. 

William H. Bradley M.D., Jamal Rahaman M.D.  Pediatric Gynecologic Cancer. Pediatric, Adolescent and Young Adult Gynecology Blackwell Publishing, Oxford, UK.  Pp 390-397

Konstansin Zakashansky M.D., William H. Bradley M.D., Farr Nezhat M.D.  Update in Radical Hysterectomy.  Current Opinions in Obstetrics and Gynecology.  2008 Feb:20(1):14-9.

Abstracts

An open label, non-randomized multisite phase II trial combining bevacizumab, atezolizumab and rucaparib for the treatment of previously treated recurrent and progressive endometrial carcinoma: Short title the EndoBARR Trial.  March 19, 2021.  Society  of Gynecologic Oncology Annual Meeting

Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy . Rebecca Arend primary author.  March 19, 2021, Society  of Gynecologic Oncology Annual Meeting

Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study.  Roisin O'Cearbhaill primary author.  March 19, 2021, Society of Gynecologic Oncology Annual Meeting

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.  K Moore MD, N Colombo MD, G Scambia MD, B-G Kim MD, PhD,⁴A Oaknin MD, PhD, M Friedlander MD, A Lisyanskaya MD, A Floquet MD, A Leary MD, G S Sonke MD, PhD, C Gourley MD, PhD^, S Banerjee MD, PhD, A Oza MD,
A González-Martín MD, PhD, C Aghajanian MD, W Bradley MD, E S Lowe MD, ScM, R Bloomfield MSc, P DiSilvestro MD.  Oct 20, 2018, Munich, Germany, European Society of Medical Oncology

Surgeon and Patient Factors Related to False-Positive (FP) Identification of Sentinel Lymph Nodes (SLN) with Indocyanine Green (ICG) in Women with Endometrial Cancer.  March 24-27, 2018, New Orleans, LA.  Society of Gynecologic Oncology

Premal H. Thaker, William H. Bradley, Charles A. Leath, Camille C. Gunderson, Nicholas Borys, Khursheed Anwer, Lauren Musso, Ronald D. Alvarez.  Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.  American Society of Clinical Oncology, General Meeting, June 2017

K. Anwer, J. Matsuzaki,  W. Bshara, A. Lugade, A. Omilian, P.H. Thaker, W.H. Bradley, C.A. Leath, C. Gunderson, J. Fewell, N. Borys, L. Musso, R.D. Alvarez, K. Odunsi. Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.  American Society of Clinical Oncology-STIC.  February, 2017 (Abstract 156).

Premal H. Thaker, Charles A. Leath, William Hampton Bradley, Kathleen N. Moore, Nicholas Borys, Khursheed Anwer, Ronald David Alvarez; Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer. Abstract Number: TPS5605. American Society of Clinical Oncology, June, 2016.  Journal of Clinical Oncology. 34, 2016 (suppl; abstr TPS5605)

Premal H. Thaker M.D., William E. Brady, Ph.D., William H. Bradley M.D., Khursheed Anwer, Ph.D., Ronald D. Alvarez, M.D., Phase I study of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with pegylated liposomal doxorubicin in recurrent or persistent epithelial ovarian, Fallopian tube, or primary peritoneal cancer patients: An NRG/GOG study. Abstract #148479, American Society of Clinical Oncology, May-June, 2015

William H. Bradley, M.D., Kevin Eng, Ph.D., David G. Mutch, M.D., Min Le, Ph.D., A. Craig Mackinnon, M.D., Ph.D., Christina Kendziorski, Ph.D., Janet S. Rader, M.D.  Gene expression levels in archived FFPE ovarian carcinoma samples: Comparison of qPCR with gene expression microarray in a 9 core pathway predictive treatment model in serous ovarian carcinoma.  Abstract #330, Society of Gynecologic Oncology Annual Meeting, March 2013.

William H. Bradley, M.D., Analisa DiFeo, Ph.D., Jamal Rahaman, M.D., Peter Dottino, M.D., John Martignetti, M.D., Ph.D.  The tumor suppressor KLF6, lost in a majority of ovarian cancer cases, represses VEGF expression levels.  Abstract#130, Volume 120, Issue 1, Supplement 1. (March 2011)

Valentin Kolev, M.D., Rachel Zhang, William H. Bradley, M.D., Rashida N'gouamba, Peter Dottino, M.D., Jamal Rahaman, M.D., Monica Hayes, M.D.  Sequential chemotherapy and radiation therapy for the adjuvant treatment of uterine papillary serous carcinoma.  Abstract#217, Volume 120, Issue 1, Supplement 1. (March 2011)

B. Bonacci, B. Wakim, L. Reddy, E. Hammelev, Janet Osborne, M.D., William H. Bradley, M.D., J. Verbsky, Denise Uyar, M.D.  Induced T regulatory cells: A potential role in the tumorigenesis of endometrial cancer.  Gynecologic Oncology.  Abstract #199, Volume 116, Issue 3, Supplement 1. (March 2010)

William H. Bradley, M.D., Konstantin Zakashansky, M.D., Nimesh P. Nagarsheth, M.D., Farr Nezhat, M.D., George Hagopian, M.D., Herb Gretz, M.D., Linus Chuang, M.D., Peter Dottino, M.D., Jamal Rahaman, M.D.. Laparoscopic Management of Endometrioid Carcinoma.  Gynecologic Oncology.  Abstract #163. Volume 108, Issue 3, Supplement 1, Pages S1-S182 (March 2008)

Konstantin Zakashansky, M.D., William H. Bradley, M.D., Peter Dottino, M.D., Valentin Kolev, M.D., Nimesh P. Nagarsheth, M.D., Farr R. Nezhat, M.D., Herbert Gretz, M.D., Jamal Rahaman, M.D.  In Vitrio Platinum Resistance in the Extreme Drug Resistance (EDR) Assay as a Predictor of Progression Free Interval in Primary Advanced Stage Ovarian Cancer.  Gynecologic Oncology.  Abstract #104. Volume 108, Issue 3, Supplement 1, Pages S1-S182 (March 2008)

Konstantin Zakashansky, M.D., William H. Bradley, M.D., Jamal Rahaman, M.D., Peter Dottino, M.D., Cathey Ester, PhD, William A. Ricketts, PhD.  Comparative Genomic Hypridiztion (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma.  Gynecologic Oncology.  Abstract #89. Volume 108, Issue 3, Supplement 1, Pages S1-S182 (March 2008)

William H. Bradley, M.D., Paul Lima, MS, Lisa Rogers, BS, Charles Blomquist, PhD, Levi S Downs, M.D.  Enzymatic Activity of Cathepsin B is Increased in Malignant Endometrial Tissue.  Poster Presentation, 52nd Annual Meeting of the Society for Gynecologic Investigation.  Abstract #903.

William H. Bradley, M.D., Peter Argenta, M.D., Levi Downs, M.D., Patricia Judson, M.D., Linda Carson, M.D., Matthew Boente, M.D.. Implications of Hysteroscopy on Peritoneal Cytology in Endometrial Cancer.  Poster, Society of Gynecologic Oncology 35th Annual Meeting, San Diego, California, February 7-11, 2004

Melissa Geller, M.D., William H. Bradley, M.D., Patricia Judson, M.D., Levi Downs, M.D., Matthew Boente, M.D., Linda Carson, M.D., Peter Argenta, M.D. Expression of C-kit Antigen in Low and High Grade Endometrial Stromal Sarcomas; Outcomes and Recurrence Patterns as Related to C-Kit. Poster, Society of Gynecologic Oncology 35h Annual Meeting, San Diego, California, February 7-11, 2004

Johnny Hyde Jr., Michael A. Gold, Nick P. Taylor, Matthew A. Powell, David G. Mutch, William H. Bradley, Melissa A. Geller, Peter A. Argenta, David E. Cohn, Kimberly E. Resnick, Charles A. Leath III, Warner K. Huh. Endometrial Stromal Sarcoma: A Multi-center Retrospective Review. Society of Gynecologic Oncology 36th Annual Meeting.  Miami, Fl, March, 2005